SCHEMBL6134623

SCHEMBL6134623

COCCCCCOc1ccccc1-c1cnc(N)s1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
LIMK1 P53667 1/20 0.41
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
NPC1 O15118 2/20 0.41
MAPT P10636 2/20 0.41
RAB9A P51151 2/20 0.41
KDM4E B2RXH2 5/20 0.41
GAA P10253 1/20 0.41
POLB P06746 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ADRB2 P07550 1/20 0.39
TP53 P04637 1/20 0.38
APP P05067 1/20 0.37
NCF1 P14598 1/20 0.37
MCHR1 Q99705 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6134626 0.75 RAB9A (0.72) HDAC1HDAC6ALDH1A1SMN1; SMN2NPC1
SCHEMBL8748691 0.71 KDM4E (0.44) ALDH1A1SMN1; SMN2NPC1MAPTKDM4E
SCHEMBL19981533 0.70 LIMK1 (0.55) LIMK1ALDH1A1SMN1; SMN2NPC1MAPT
SCHEMBL263965 0.69 MCHR1 (0.43) KDM4EGAAL3MBTL1ADRB2NCF1
SCHEMBL11953304 0.69 LIMK1 (0.54) LIMK1ALDH1A1SMN1; SMN2NPC1MAPT
SCHEMBL20170926 0.69 CYP1A2 (0.69) HDAC6ALDH1A1SMN1; SMN2NPC1MAPT
SCHEMBL5083181 0.68 KDM4E (0.41) ALDH1A1SMN1; SMN2NPC1KDM4EGAA
SCHEMBL5083191 0.68 KDM4E (0.41) ALDH1A1SMN1; SMN2NPC1KDM4EGAA
Bromide SCHEMBL14053627 0.67 FBP1 (0.53) ALDH1A1SMN1; SMN2KDM4EGAAAPP
SCHEMBL478309 0.67 HTR7 (0.56) ALDH1A1SMN1; SMN2MAPTRAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050261177-A1 Compound ASTELLAS PHARMA INC. (JP) 2005-11-24 US disclosed
EP-1366066-A2 CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-12-03 EP disclosed
WO-2002072621-A2 CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261177-A1 Compound MANBA, MAN2B1, MAN2A1 HDAC3 1145/4885HDAC1 563/4885HDAC2 1948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.